Abstract
Out of the 15 discrete proteins encoding the total amount of genetic information in the chromosomes of human immunodeficiency virus type 1; three perform the vital enzymatic functions i.e. a reverse transcription, an integration, and proteolysis. The HIV integrase is the new validated drug target against AIDS amongst all essential enzymes due to the lack of the human homologue. In last few years quite, a few but potent inhibitors inhibiting HIV-1 integrase have been recognized and hence have gained a state-of-the-art for treating the infection caused by HIV-1. The greater understanding of HIV-integrase biological structure has further lead to continuous efforts for the proposal of novel inhibitors targeting diverse steps in the progression of integration with the primary goal to overcome resistance due to the rapid occurrence of integrase mutations in the treated patients. This review is focused on various aspects of the recently approved HIVintegrase inhibitor “dolutegravir”, its efficacy, safety profiles with the clinical data and molecular modeling studies highlighting its importance over the already approved HIV-integrase inhibitors.
Keywords: AIDS, HIV, integrase, dolutegravir, reteroviral, homologue.
Current HIV Research
Title:A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir
Volume: 12 Issue: 5
Author(s): Bawneet K. Narang, Gurpreet K. Grewal, Subhajit Roy, Jitender Bariwal, Manish K. Gupta and Ravindra K. Rawal
Affiliation:
Keywords: AIDS, HIV, integrase, dolutegravir, reteroviral, homologue.
Abstract: Out of the 15 discrete proteins encoding the total amount of genetic information in the chromosomes of human immunodeficiency virus type 1; three perform the vital enzymatic functions i.e. a reverse transcription, an integration, and proteolysis. The HIV integrase is the new validated drug target against AIDS amongst all essential enzymes due to the lack of the human homologue. In last few years quite, a few but potent inhibitors inhibiting HIV-1 integrase have been recognized and hence have gained a state-of-the-art for treating the infection caused by HIV-1. The greater understanding of HIV-integrase biological structure has further lead to continuous efforts for the proposal of novel inhibitors targeting diverse steps in the progression of integration with the primary goal to overcome resistance due to the rapid occurrence of integrase mutations in the treated patients. This review is focused on various aspects of the recently approved HIVintegrase inhibitor “dolutegravir”, its efficacy, safety profiles with the clinical data and molecular modeling studies highlighting its importance over the already approved HIV-integrase inhibitors.
Export Options
About this article
Cite this article as:
Narang K. Bawneet, Grewal K. Gurpreet, Roy Subhajit, Bariwal Jitender, Gupta K. Manish and Rawal K. Ravindra, A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir, Current HIV Research 2014; 12 (5) . https://dx.doi.org/10.2174/1570162X12666140807150753
DOI https://dx.doi.org/10.2174/1570162X12666140807150753 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD8+ Cell Noncytotoxic Antiviral Response in Long-Term HIV-1 Infected Former Blood Donors in China
Current HIV Research The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Entry of Oximes into the Brain: A Review
Current Medicinal Chemistry Gene Therapy in Plastic and Reconstructive Surgery
Current Gene Therapy Antihemostatic Strategies of Blood-Feeding Arthropods
Current Drug Targets - Cardiovascular & Hematological Disorders Filling the Gaps between the In Vivo and In Vitro Microenvironment: Engineering of Spheroids for Stem Cell Technology
Current Stem Cell Research & Therapy Controlling HIV-1 Rev Function
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Host Defense Peptides and the New Line of Defence Against Multiresistant Infections
Protein & Peptide Letters Drug Eluting Stents and Beyond
Current Pharmaceutical Design Antiviral Strategies: The Present and Beyond
Current Molecular Pharmacology Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease
Current Pharmaceutical Design Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Dendritic Cells in Innate Immune Responses Against HIV
Current Molecular Medicine Therapeutics Interventions with Anti-Inflammatory Creams in Post Radiation Acute Skin Reactions: A Systematic Review of Most Important Clinical Trials
Recent Patents on Inflammation & Allergy Drug Discovery TB Diagnostics – Old and New
Current Respiratory Medicine Reviews Treatment of Inflammatory Diseases with Mesenchymal Stem Cells
Inflammation & Allergy - Drug Targets (Discontinued) IL-1β and IL-1Ra Variant Profiles in Turkish Patients with Diabetic Peripheral Neuropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets o-Alkylselenenylated Benzoic Acid Accesses Several Sites in Serum Albumin According to Fluorescence Studies, Raman Spectroscopy and Theoretical Simulations
Protein & Peptide Letters